Walgreens has reached an agreement to transition into a private entity, yet the details of this arrangement are quite intricate. There is a compelling argument for purchasing the stock even amidst this deal.
Walgreens Boots Alliance (WBA 0.29%) has faced challenges that have made it a less appealing stock for investors over the past few years, primarily due to several corporate miscalculations. The situation deteriorated to the point where the board concluded that the most effective strategy would involve a turnaround under the management of private investors. This arrangement indicates that Walgreens is set to exit the public trading sphere within the next year. However, the narrative doesn’t end there, as more daring investors may still find value in the stock due to a unique aspect of the take-private transaction. Here’s what investors need to understand about this pivotal change.
Transitioning from Industry Powerhouse to Private Ownership
Among the few major pharmacy retailers, Walgreens stands out as one of the key players. Historically, it was recognized for rapid growth and expansion, but eventually, the market experienced saturation. It wasn’t uncommon to find a Walgreens located on one corner while its competitors were just a stone’s throw away. Therefore, it’s not surprising that growth within the sector has plateaued, leading to stagnation.
Image source: Getty Images.
In response to these challenges, Walgreens sought alternative avenues to fuel its growth. The company attempted to enter the pharmacy benefits management sector, but the results fell short of expectations. Subsequently, it initiated a plan to establish a network of healthcare clinics, which also did not yield the desired outcomes. Once considered a candidate for Dividend King status, Walgreens ultimately had to cut and eventually eliminate its dividend, a decision that coincided with the announcement of the take-private agreement.
Recently, Walgreens has been focused on restructuring its operations, which includes closing several retail locations. However, this revamp is anticipated to be a significant endeavor that poses challenges in the public market. Investors generally react negatively to companies undergoing contraction, which is precisely the path Walgreens is taking. Consequently, in early March, the company entered into an agreement to be taken private by Sycamore Partners Management at a price of $11.45 per share, with the transaction expected to finalize in the latter half of 2025.
What Factors Are Causing Walgreens’ Stock to Trade Above the Acquisition Price?
In typical acquisition scenarios, the stock price of the company being taken over usually trades for a slight discount compared to the agreed-upon acquisition price. This is largely due to the uncertainty surrounding the completion of the deal. However, in the case of Walgreens, its shares are trading at a marginal premium above the acquisition price, indicating that there may be unusual circumstances at play.
The twist here is that Sycamore Partners has intentions to sell Walgreens’ medical clinic business. As part of this strategy, Walgreens shareholders will receive a “chit” that could potentially be valued at up to $3 per share, contingent on the eventual sales price obtained for the clinic business. Therefore, investors who are currently purchasing Walgreens shares above $11.45 are essentially investing in this chit, as they are accepting a potential loss on the Walgreens shares.
However, there is a significant concern regarding the timing of the sale of the clinic business. Additionally, there is no assurance regarding the sales price that Sycamore Partners will achieve from the transaction. Consequently, the $3 chit could either end up being worthless, or the duration before any profits materialize could be extended, diminishing the time value of the potential gain. The uncertainty surrounding the outcome makes it impossible to predict the financial implications accurately.
Given these factors, purchasing Walgreens stock today may not be advisable for most investors, especially those with a conservative investment approach. Nevertheless, more aggressive investors who are open to special situations might find it appealing, as the clinic business likely holds some intrinsic value. Still, this investment remains high-risk, with a maximum upside potential of approximately 25%. While this may appear substantial, it is only truly beneficial if the cash flow is realized in a timely manner.
Walgreens Will Transition Away from Public Trading Within a Year, But Its Legacy Will Endure
In the near future, within a year, Walgreens will cease to exist as a publicly traded company. However, it will remain a point of interest for investors due to the $3 chit associated with the impending sale of the medical clinic business. Looking further ahead, it is quite plausible that Walgreens may re-enter the public market in the future, albeit with entirely different shares and hopefully a more robust position within the industry. For now, it is crucial that only investors willing to take on higher risks consider Walgreens as a viable option.
